Drug Trial Radar · NCT06810687
Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Jan 30, 2025
Primary completion
Jul 30, 2027
Study completion Jan 30, 2028
Sponsor
- Lead sponsor
- Atlantic Health SystemAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 100 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.
Conditions
- Urinary Tract Infection (Diagnosis)
Interventions
Methenamine Hippurate 1g BDDrug
Antibiotic prophylaxis
Antibiotic prophylaxisOther
Antibiotic prophylaxis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of urinary tract infectionTime frame: Within 6 weeks after the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Atlantic Health
Morristown, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.